Biogen And Abbott Labs Announce Positive Top-Line Results From First Registrational Trial For Daclizumab HYP. Tekmira Announces Additional Clinical Trial Of TKM-PLK1. Print E-mail
By Staff and Wire Reports   
Tuesday, 09 August 2011 19:36
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 9, 2011.

Biogen Idec Inc (NASDAQ:BIIB)
and Abbott Laboratories (NYSE:ABT) announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting multiple sclerosis (RRMS) over one year.

In addition to SELECT, DAC HYP is being studied in a Phase 3 registrational clinical trial called DECIDE, which is enrolling patients. DECIDE is evaluating the efficacy and safety of once-monthly subcutaneous DAC HYP as a monotherapy compared to interferon beta 1-a therapy over two to three years of treatment.


Tekmira Pharmaceuticals Corp, (NASDAQ:TKMR) along with its collaborators at the United States National Cancer Institute (NCI), announced that they have received approval from the FDA to proceed with a new Phase 1 clinical trial for Tekmira's lead oncology product, TKM-PLK1.

This trial, run in parallel with the ongoing Phase 1 trial of TKM-PLK1, provides Tekmira with an early opportunity to validate the drug's mechanism of action. The NCI trial is a Phase 1 multiple-dose, dose escalation study testing TKM-PLK1 in patients with unresectable colorectal, pancreatic, gastric, breast, ovarian and esophageal cancers with liver metastases, or primary liver cancers. These patients represent a significant unmet medical need as they are not well served by currently approved treatments.

Typically reserved for later stage trials, pharmacodynamic measurements are facilitated in this Phase 1 trial in part through the unique capabilities of the NCI Surgery Branch. Secondary objectives of the trial include establishing maximum tolerated dose and to evaluate response rate.

Also Tuesday:

Accuray Incorporated (Nasdaq:ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Wedbush Life Sciences: Management Access Conference in New York on Wednesday, August 17, 2011 at 9:10 a.m. ET/6:10 a.m. PT.

Adeona Pharmaceuticals, Inc. (AMEX:AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its 2nd quarter 2011 investor conference call on Monday, August 15, 2011, at 2:00pm EDT.

American Oriental Bioengineering, Inc. (NYSE:AOB)
, (the "Company" or "AOB"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced financial results for the second quarter ended June 30, 2011.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
today reported financial results for the second quarter ended June 30, 2011.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 2011 at 10:00 a.m. ET.

BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Eurasia, today announced its financial results for the second quarter ended June 30, 2011 and provided a corporate update.

China Biologic Products, Inc. (NASDAQ:CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), today reported its results for the three months ended June 30, 2011.

Echo Therapeutics, Inc. (Nasdaq:ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the unveiling of a much anticipated demonstration video on the Company's website at

GenVec, Inc. (NASDAQ:GNVC) today announced its financial results for the three months and six months ended June 30, 2011.

Oncothyreon Inc. (Nasdaq: ONTY) announced today that Julie Eastland, Chief Financial Officer and Vice President, Corporate Development, will present at the Wedbush Securities 2011 Life Sciences Management Access Conference in New York on Tuesday, August 16, 2011, at 11:10 a.m. Eastern Time.

PAREXEL International Corporation (NASDAQ:PRXL) today reported financial results for the fourth quarter and fiscal year ended June 30, 2011.

Tengion, Inc. (Nasdaq:TNGN) today provided a business update and reported its financial results for the second quarter ended June 30, 2011.

Verenium Corporation (Nasdaq:VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the second quarter and six months ended June 30, 2011.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus